INCYIncyte CorporationFinished
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
MPN (Myeloproliferative Neoplasms)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 47 (final count)
- Started
- Apr 25, 2017
- Main results expected
- Oct 30, 2024
- Fully finished
- Oct 30, 2024
- Results posted
- Nov 18, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants Who Achieved Complete Response (CR) as Determined by Investigator Assessment According to the Response Criteria for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
Measured over: up to 2513 days (120 21-day treatment cycles)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03011372 · record last updated 2025-11-18 · checked 2026-11-09 15:42 UTC